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Background:  Inﬂammatory  bowel  disease  (IBD)  has  a  physical,  psychological  and  social  impact,
often compromising  the  patient’s  ability  to  perform  daily  activities.  Recently  a  new  measure-
ment for  disability  in  IBD  was  developed.  The  Inﬂammatory  Bowel  Disease-Disability  Score
(IBD-DS) comprises  the  following  domains:  mobility,  self-care,  major  daily  life  activities,
gastrointestinal-related  problems,  mental  health  and  interaction  with  the  environment.  The
aim of  our  study  was  to  translate  to  Portuguese  and  to  validate  the  IBD-DS.
Methods:  Eighty-ﬁve  patients,  55  with  Crohn’s  disease  (CD)  and  30  with  ulcerative  colitis  (UC),
completed  the  Portuguese  version  of  the  IBD-DS  and  the  short  inﬂammatory  bowel  disease
questionnaire  (SIBDQ-10  questions).  Disease  activity  was  assessed  using  the  Harvey--Bradshaw
(HB) for  CD  and  partial  Mayo  score  (pMayo)  for  UC.  Pearson’s  correlation  coefﬁcient  was  used  to
assess the  correlation  between  the  IBD-DS  and  SIBDQ.  The  Student’s  t-test  was  used  to  compare
the mean  of  IBD-DS  between  active  and  inactive  disease.  Statistical  analysis  was  performed  with
SPSS 21.0  and  the  statistical  level  of  signiﬁcance  (˛)  was  established  at  5%.
Results:  In  our  study,  a  signiﬁcant  negative  correlation  between  the  IBD-DS  and  the  SIBDQ  was
observed (r  =  −0.858,  p  <  0.001  for  CD  and  r  =  −0.933,  p  <  0.001  for  UC).  There  was  a  statistically
signiﬁcant  difference  of  the  mean  of  IBD-DS  between  inactive  vs.  active  disease  (93.78  vs.
117.57, p  =  0.016  for  CD  and  78.96  vs.  137.14,  p  <  0.001  for  UC).
Conclusion:  The  Portuguese  version  of  the  inﬂammatory  bowel  disease-disability  score  has  a
strong correlation  with  patients’  quality  of  life  and  clinical  disease  activity  and  was  shown  to
be a  valid  tool  to  measure  disability  in  patients  with  inﬂammatory  bowel  disease.
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Incapacidade  na  Doenc¸a Inﬂamatória  Intestinal:  Traduc¸ão  Para  Português  e  Validac¸ão
do  ‘‘Inﬂammatory  Bowel  Disease  --  Disability  Score’’
Resumo
Introduc¸ão:  O  impacto  físico,  psicológico  e  social  da  doenc¸a  inﬂamatória  intestinal  (DII)  com-
promete frequentemente  a  capacidade  do  doente  realizar  as  suas  atividades  de  vida  diária.
Foi desenvolvido  recentemente  um  novo  questionário  de  avaliac¸ão  de  incapacidade  na  DII.
O ‘‘Inﬂammatory  Bowel  Disease  --  Disability  Score’’  (IBD-DS)  contempla  a  avaliac¸ão  de  difer-
entes domínios  de  incapacidade  na  DII:  mobilidade,  autocuidado,  principais  atividades  de  vida
diária, saúde  mental,  problemas  gastrointestinais  e  impacto  social.  O  objetivo  deste  estudo  foi
a traduc¸ão  do  IBD-DS  para  a  língua  portuguesa  e  a  validac¸ão  das  suas  propriedades  de  avaliac¸ão
de incapacidade  em  doentes  portugueses  com  DII.
Material  e  Métodos: Um  total  de  85  doentes,  55  com  doenc¸a  de  Crohn  (DC)  e  30  com  colite
ulcerosa (CU),  preencheram  a  versão  portuguesa  do  IBD-DS  e  um  questionário  de  qualidade
de vida  na  DII  (SIBDQ-10  questões).  A  actividade  da  doenc¸a  foi  avaliada  usando  o  índice  de
Harvey--Bradshaw  (HB)  para  a  DC,  e  o  score  parcial  de  Mayo  (pMayo)  para  a  CU.  A  correlac¸ão
entre o  IBD-DS  e  o  SIBDQ  foi  determinada  através  do  coeﬁciente  de  correlac¸ão  de  Pearson.  O
teste t  para  amostras  independentes  foi  utilizado  para  comparar  a  média  do  IBD-DS  entre  os
doentes com  doenc¸a  ativa  e  inativa.  A  análise  estatística  foi  realizada  com  o  SPSS  21.0,  o  nível
de signiﬁcância  (˛)  foi  estabelecido  em  5%.
Resultados:  No  nosso  estudo  veriﬁcou-se  uma  forte  correlac¸ão  negativa  entre  o  IBD-DS  e  o  SIBDQ
(r =  −0.858,  p  <  0,001  para  a  DC  e  r =  −0.933,  p  <  0,001  para  a  CU).  Foi  observada  uma  diferenc¸a
estatisticamente  signiﬁcativa  do  valor  médio  do  IBD-DS  entre  doentes  com  doenc¸a  inativa  vs.
ativa (93.78  vs.  117.57,  p  =  0,016  para  a  DC  e  78.96  vs.  137.14,  p  <  0,001  para  a  CU).
Conclusão:  A  versão  portuguesa  do  IBD-DS  apresentou  uma  boa  correlac¸ão  com  a  qualidade  de
vida e  atividade  da  DII,  apresentando-se,  deste  modo,  como  uma  ferramenta  válida  na  avaliac¸ão
de incapacidade  na  DII.
©  2014  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.U.  Todos




















The  inﬂammatory  bowel  disease  (IBD)  comprises  Crohn’s  dis-
ease  (CD)  and  ulcerative  colitis  (UC),  which  are  chronic
diseases  with  a  complex  multifactorial  etiology  and  a
relapsing-remitting  disease  course.  Clinically,  they  can
present  with  a  diverse  set  of  intestinal,  extra-intestinal
and  systemic  symptoms.  The  chronic  nature  often  requires
repeated  hospitalizations  and  lifelong  treatments,  which
compromise  all  domains  of  patient’s  life  (physical,  social
and  psychological).
A  more  holistic  approach  to  chronic  diseases,  namely  IBD,
requires  particular  consideration  for  the  quality  of  life  and
disability  related  to  disease.  The  World  Health  Organization
deﬁnes  quality  of  life  as  ‘‘an  individual’s  perception  of  their
position  in  life  in  the  context  of  the  culture  and  value  sys-
tems  in  which  they  live  and  in  relation  to  their  goals,  expec-
tations,  standards  and  concerns’’.1 In  contrast,  disability  is
the  human  experience  of  impaired  body  functions  and  struc-
tures,  activity  limitations,  and  participation  restrictions  in
the  interaction  with  environmental  factors.2 Thus,  the  dis-
ability  evaluation  is  an  objective  determination  and  differs
from  subjective  assessments  such  as  quality  of  life.
Until  now,  attention  has  been  focused  on  the  impact  of
IBD  on  patient’s  quality  of  life.3--5 On  the  other  hand,  disabil-
ity  in  IBD  remains  poorly  studied,  since  only  work-related
disability  in  IBD  was  reported  in  the  literature.6--8
3
l
oRecently,  a  new  questionnaire  to  evaluate  disability  in  IBD
as  developed.9 The  Inﬂammatory  Bowel  Disease-Disability
core  (IBD-DS)  comprises  the  following  domains:  mobility,
elf-care,  major  daily  life  activities,  gastrointestinal-related
roblems,  mental  health  and  interaction  with  the  envi-
onment.  During  the  initial  evaluation,9 the  questionnaire
eemed  to  be  sufﬁciently  valid  and  useful  for  evalua-
ion  of  disability  in  IBD,  however,  for  a more  widespread
se  its  validation  in  more  studies  is  necessary,  particu-
arly  in  different  countries  and  ethnicities.  Thus  the  aim
f  our  study  was  not  only  to  translate  to  Portuguese  the
BD-DS  but  also  to  apply  and  validate  it  in  Portuguese
atients.
.  Methods
.1.  Inﬂammatory  Bowel  Disease  Disability  Score  --
uestionnaire
he  IBD-DS,  a  tool  for  assessing  disability  reported  by
atients,  comprises  a  total  of  58  questions  grouped  into  6
omains.  Fifty-four  questions  were  scored  according  to  a  5-
oint  Likert  scale  (1  --  no  limitation;  2  --  slight  limitation,
 --  moderate  limitation,  4  --  severe  limitation,  5  --  worst
imitation)  and  four  questions  were  a choice  between  a  yes



























































































.2.  Translation  and  cross-cultural  adaptation
he  initial  translation  of  the  questionnaire  (in  English)  to
he  target  language  (Portuguese)  was  performed  by  two
ilingual  translators  (Portuguese  and  English).  The  trans-
ators  were  previously  informed  about  the  objectives  and
nderlying  concepts  of  the  study,  and  did  not  maintain  any
ontact  during  the  process  of  translation.  Two  independent
ranslations  were  obtained.  A  committee  composed  by  two
astroenterologists,  with  high  ﬂuency  in  English  language
nd  experienced  in  following  patients  with  IBD,  evaluated
he  equivalence  of  content  between  these  versions  and  the
riginal  and  did  the  necessary  changes  to  obtain  a prelimi-
ary  version.
To  verify  the  comprehensiveness  of  the  questionnaire,
he  preliminary  version  was  ﬁlled  by  a  sample  of  6
atients.  Subsequently,  and  following  the  doubts  reported
y  patients,  the  previously  referred  committee  made
he  necessary  modiﬁcations  to  obtain  a  ﬁnal  version.
Annex  1).
. Patients
etween  June  and  November  2013,  patients  with  the
iagnosis  of  IBD  (UC  or  CD),  with  follow-up  in  our  gastroen-
erology  department,  were  prospectively  interviewed  during
n  attending  physician  visit.  We  excluded  patients  seen
n  urgent  context,  hospitalized  patients,  as  well  as  those
nable  to  comprehend  the  questionnaire.
The  patients  were  informed  about  the  study’s  charac-
er  and  those  who  agreed  to  participate  were  enrolled  and
igned  an  informed  consent  form.
Patients  were  invited  to  ﬁll  the  Portuguese  version  of  the
BD-DS  and  a  questionnaire  to  assess  quality  of  life  --  the
hort  inﬂammatory  bowel  disease  questionnaire  (SIBDQ).
Patients’  current  disease  state,  with  respect  to  disease
ctivity,  was  assessed  using  the  Harvey-Bradshaw  (HB)  for  CD
nd  partial  (excluding  sigmoidoscopy)  Mayo  score  (pMayo)
or  UC.  Crohn’s  disease  was  considered  in  remission  when
he  HB  was  <5,10 and  UC  was  considered  in  remission  in
atients  with  a  pMayo  ≤2  and  no  subscore  >1.11
The  study  of  demographic  and  clinical  variables  (disease
uration,  topography  of  intestinal  lesions,  previous  surgery
r  hospitalization  related  to  IBD,  extra-intestinal  mani-
estations  and  medical  treatment)  was  conducted  through
nalysis  of  medical  records  from  the  beginning  of  the  disease
ntil  the  time  of  study.
Ninety-six  patients  with  IBD  ﬁlled  the  IBD-DS,  however
1  (11.4%)  were  excluded  because  they  were  not  correctly
lled.  The  85  questionnaires  correctly  ﬁlled  were  used  to
est  the  validity  and  internal  consistency  of  the  IBD-DS.  To
tudy  the  reproducibility  of  IBD-DS,  within  4  weeks  after
hey  completed  the  IBD-DS,  a  subset  of  17  patients  were
sked  to  ﬁll  the  IBD-DS  again  (test/retest  reliability).
. Statistical analysissing  the  Gpower® software  and  taken  into  consideration
he  statistical  tests  employed,  we  determined  the  minimum
ample  size  to  be  hundred  eighteen  patients.
m
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The  statistical  analysis  was  performed  using  the  SPSS  --
tatistical  Package  for  the  Social  Sciences  --  version  21.0.
he  statistical  level  of  signiﬁcance  (˛)  was  established  at
%.
Descriptive  data  were  described  as  mean  ±  standard
eviation  (SD)  for  quantitative  variables  and  proportions  for
ualitative  ones.
Pearson’s  correlation  coefﬁcient  was  used  to  assess  the
orrelation  between  the  IBD-DS  and  SIBDQ.
The  Student’s  t-test  for  independent  samples  was  used
o  compare  the  mean  of  IBD-DS  between  active  and  inactive
isease.
To  compare  the  means  IBD-DS  for  variables  age  at  diagno-
is  and  topography  of  intestinal  lesions  was  used  the  analysis
f  variance  (one-way  ANOVA)  and  for  gender,  history  of
revious  surgery  or  hospitalization,  extra-intestinal  mani-
estations  and  employment  status  was  used  the  t-test  for
ndependent  samples.
The  internal  consistency  of  the  IBD-DS  was  measured  with
ronbach’s  alpha  coefﬁcient  and  the  reproducibility  was
ssessed  using  the  intraclass  correlation  coefﬁcient  (ICC).




he  study  population  included  55  patients  with  CD  and  30
ith  UC,  53  (62.4%)  females,  with  a  mean  age  of  39.3  ±  12.3
ears  (17--77  years).  The  55  patients  with  CD  included  in  the
tudy  had  a  mean  age  of  38.6  ±  11.9  years  (17--77  years)  and
6  (65.5%)  were  female.  The  30  patients  with  UC  included  in
he  study  had  a mean  age  of  40.6  ±  13.3  years  (19--65  years)
nd  17  (56.7%)  were  female.  Twenty-seven  patients  (31.8%),
ll  with  CD,  had  a  previous  surgery  related  to  IBD,  one
f  them  with  an  ileostomy.  Seven  patients  (8.2%),  all  with
D,  had  a history  of  perianal  disease.  Forty-seven  patients
55.3%),  40  with  CD  and  7  with  UC,  had  a previous  hospital-
zation  related  to  IBD.
Eight  patients  (9.4%),  4  with  CD  and  4  with  UC,  were
urrently  under  a  sick  leave  and  9  (10.6%)  patients  with  CD
ere  on  a  disability  pension.
The  clinical  details  of  patients  with  CD  or  UC  are  shown
n  Tables  1  and  2,  respectively.
.2.  IBD-DS  in  Crohn’s  disease
or  patients  with  CD,  the  mean  values  of  quality  of  life  and
isability,  assessed  by  SIBDQ  and  IBD-DS,  were  44.8  ±  11.9
nd  101.6  ±  30.1,  respectively.
The  quality  of  life  in  patients  with  CD  showed  a  strong
egative  correlation  with  the  IBD-DS  (r  =  −0.858,  p  <  0.001).
Patients’  current  disease  state,  with  respect  to  disease
ctivity,  assessed  using  the  Harvey--Bradshaw  (HB),  showed
hat  37  (67.3%)  patients  with  CD  were  in  clinical  remission.
There  was  a  statistically  signiﬁcant  difference  of  the
ean  of  IBD-DS  between  inactive  vs.  active  disease
93.78  ±  24.09  vs.  11.757  ±  35.37,  p  =  0.016).
In  patients  with  CD,  the  study  of  clinical  variables  also
howed  signiﬁcantly  higher  scores  of  disability  in  women
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Table  1  Clinical  characteristics  of  Crohn’s  disease
patients.
Variable  Patients  (n  =  55)
Duration  of  IBD  (years)
mean  ±  SD  6.7  ±  4.9
min--max  1--17
Age at  diagnosis,  n  (%)
≤16  years  10  (18.2%)
17--40 years  38  (69.1%)
≥40 years  7  (12.7%)
Location,  n  (%)
Ileal  32  (58.2%)
Colonic  4  (7.3%)
Ileocolonic  19  (34.5%)
Behavior,  n  (%)
Non-stricturing,  non-penetrating  23  (41.8%)
Stricturing  15  (27.3%)
Penetrating 17  (30.9%)
Current  medical  therapy  for  IBD,  n  (%)
Steroids  3  (5.45%)
Aminosalicylates  12  (21.8%)
Azathioprine  36  (65.4%)
Biological  therapy  17  (30.1%)
Table  3  Mean  of  IDB-DS  for  clinical  variables  in  Crohn’s
disease  patients.
IBD-DS  (mean  ±  SD)  p  value
Gender
Male  88.9  ±  28.2  0.023
Female  108.2  ±  29.3
Age  at  diagnosis,  n  (%)
≤16  years  83.9  ±  23.6  0.109
17--40 years  102.9  ±  30.9
≥40  years  119.1  ±  24.3
Location
Ileal  99.9  ±  28.8  0.898
Colonic 104.2  ±  12.8




96.5  ±  32.4  0.518
Stricturing  102.4  ±  19.5
Penetrating 107.6  ±  34.7
Perianal  Disease 0.677
No  99.1  ±  31.9
Yes 90.6  ±  29.9
Extra-intestinal  manifestations
No 95.5  ±  27.6  0.002
Yes 125.7  ±  28.5
IBD-related  hospital  admission
No  97.5  ±  37.8  0.609
yes 103.1  ±  27.1
IBD-related  surgical  procedure
No  93.8  ±  30.8  0.052
yes 109.6  ±  27.7
Sick  leave  or  disability  pension
No 96.0  ±  29.4  0.013
yes 119.4  ±  26.2(p  =  0.023)  and  patients  with  extra-intestinal  manifestations
of  CD  (p  =  0.002).  Patients  with  a  sick  leave  or  disabil-
ity  pension  also  had  signiﬁcantly  higher  disability  scores
(p  =  0.013).  There  were  no  statistically  signiﬁcant  differ-
ence  between  the  mean  values  of  the  IBD-DS  and  the  age  at
diagnosis  (p  =  0.109),  location  (p  =  0.898)  and  disease  behav-
ior  (p  =  0.518),  perianal  disease  (p  =  0.677),  hospitalization
(p  =  0.609),  or  IBD-related  surgical  procedure  (p  =  0.052)
(Table  3).
Table  2  Clinical  characteristics  of  ulcerative  colitis
patients.
Variable  Patients  (n  =  30)
Duration  of  IBD  (years)
mean  ±  SD  6.2  ±  5.7
min--max  2--30
Age at  diagnosis,  n  (%)
<40 anos  14  (46.7%)
≥40 anos  16  (53.3%)
Location,  n  (%)
Proctitis  5  (16.7%)
Left-sided  colitis  7  (23.3%)
Pancolitis  18  (60.0%)
Current  medical  therapy  for  IBD,  n  (%)
Aminosalicylates  28  (93.3%)
Azathioprine  13  (43.3%)















h.3.  IBD-DS  in  ulcerative  colitis
or  patients  with  UC,  the  mean  values  of  quality  of  life  and
isability,  assessed  by  SIBDQ  and  IBD-DS,  were  49.1  ±  13.6
nd  92.5  ±  34.2,  respectively.
The  quality  of  life  in  patients  with  UC  showed  a  strong
egative  correlation  with  the  IBD-DS  (r  =  −0.933,  p  <  0.001).
Patients’  current  disease  state,  with  respect  to  disease
ctivity,  assessed  using  the  pMayo  score,  showed  that  23
76.7%)  patients  with  UC  were  in  clinical  remission.
There  was  a  statistically  signiﬁcant  difference  of  the
ean  of  IBD-DS  between  inactive  vs.  active  disease
78.96  ±  24.51  vs.  137.14  ±  20.58,  p  <  0.001).
Patients  with  a  sick  leave  or  disability  pension  had  sig-
iﬁcantly  higher  disability  scores  (p  =  0.006).  There  was  no
tatistically  signiﬁcant  difference  between  the  mean  val-
es  of  the  IBD-DS  and  gender  (p  =  0.061),  age  at  diagnosis
p  =  0.782),  extent  of  disease  (p  =  0.321),  presence  of  extra-
ntestinal  manifestations  (p  = 0.595)  or  previous  IBD-related
ospital  admission  (p  =  0.061)  (Table  4).
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Table  4  Mean  of  IDB-DS  for  clinical  variables  in  ulcerative
colitis patients.
IBD-DS  (mean  ±  SD)  p  value
Gender
Male  79.9  ±  23.8  0.061
Female  102.2  ±  38.3
Age at  diagnosis
≤40  years  94.4  ±  29.8  0.782
>40 years  90.8  ±  38.6
Location
Proctitis 104.4  ±  19.7  0.321
Left-sided  colitis 100.6  ±  48.6
Pancolitis  86.1  ±  30.9
Extra-intestinal  manifestations
No 93.7  ±  34.2  0.595
Yes 82.3  ±  39.8
IBD-related  hospital  admission
No  98.9  ±  34.3  0.061
Yes 71.4  ±  25.9















































































aNo 86.1  ±  28.3 0.006
Yes 134.3  ±  43.9
There  was  no  difference  between  the  mean  of  the  IBD-DS
or  CD  and  UC  (92.5  ±  34.2  vs.  101.6  ±  30.1,  p  =  0.212).
.4.  IBD-DS  --  internal  consistency  and
eproducibility
he  IBD-DS  presented  a  high  degree  of  internal  consis-
ency  (coefﬁcient  alpha:  0.85)  and  a  good  reproducibility
ICC  =  0.76,  95%  0.34--0.91).
. Discussion
ver  the  last  decades,  the  incidence  and  prevalence  of  IBD
as  been  increasing  in  Europe,  and  an  estimate  0.3%  of  the
uropean  population  suffers  from  IBD.14 In  Portugal,  a  recent
tudy,  based  on  a  pharmacoepidemiological  approach,  esti-
ated  an  increased  prevalence  of  CD  and  UC  of  42  and  43
er  100,000  in  2003  to  71  and  73  in  2007,  respectively.15 This
ncrease  in  incidence  and  prevalence  accounts  for  substan-
ial  costs  to  the  health  care  system  and  society.
The  impact  of  IBD  in  all  domains  of  the  patient’s  life  is
ubstantial  because  it  is  a  chronic  disease,  with  an  early
ge  onset  and  a  relapsing-remitting  course.  However,  when
ompared  with  other  chronic  inﬂammatory  diseases,  such  as
ultiple  sclerosis,16 it  is  surprising  how  little  is  known  about
isability  in  IBD.
A  new  tool  to  assess  disability  in  IBD  was  recently
eveloped.9 During  the  validation  of  the  score,  by  the  same
orking  group,  this  proved  to  be  sufﬁciently  sensitive  to
etect  disability  in  patients  with  IBD.
The  assessment  of  disability  in  Portuguese  patients  with
BD  is  crucial  to  provide  a  more  holistic  approach  to  the
atient.  However,  the  simple  translation  of  a  questionnaire
b
o
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o  another  language  does  not  guarantee  its  validity  and
eproducibility,  being  critical  the  evaluation  of  these
arameters  prior  to  the  widespread  application  of  the  ques-
ionnaire.
The  validity  of  the  Portuguese  version  of  the  IBD-DS  was
ssessed  by  the  comparison  of  the  IBD-DS  with  a  question-
aire  to  assess  quality  of  life  of  IBD  patients,  the  SIBDQ,
 tool  sufﬁciently  comprehensive  and  easy  to  apply.17 We
bserved  a  signiﬁcant  negative  correlation  between  the  IBD-
S  and  the  SIBDQ  (r  =  −0.858  and  r  =  −0.933,  p  <  0.001,  for
D  and  UC,  respectively),  suggesting  that  a  lower  quality  of
ife  correlated  with  a  higher  IBD-DS.  These  ﬁndings  are  cor-
oborated  by  the  study  of  Allen  et  al.  (r  =  −0.838,  p  < 0.001).9
ther  studies  further  support  the  relationship  between  qual-
ty  of  life  and  work  disability.6--8
During  the  validation  of  IBD-DS,  we  also  included  the
ssessment  of  disease  activity.  In  the  study  by  Allen  et  al.9 a
igniﬁcant  relationship  between  the  activity  of  CD,  assessed
y  Crohn’s  Disease  Activity  Index  (CDAI),  and  the  IBD-DS  was
bserved.  In  our  study,  we  chose  to  use  the  HB  index  for
ssessing  activity  in  DC,  because  it  is  easier  to  apply  and
as  a  strong  correlation  with  the  CDAI,10 and  we  showed
 statistically  signiﬁcant  difference  of  the  mean  of  IBD-DS
etween  inactive  vs.  active  disease.  We  also  showed  a  sig-
iﬁcant  relationship  between  the  activity  of  UC  and  IBD-DS,
ot  observed  by  Allen  et  al,9 allowing  us  to  enhance  the
pplicability  of  IBD-DS  in  patients  with  UC.
Recently,  another  measure  to  assess  disability  in  IBD  was
eveloped.  This  new  tool,  called  IBD-disability  index,18 com-
rises  the  categories  of  the  ‘‘International  Classiﬁcation
unctioning’’19 that  more  often  are  affected  in  patients  with
BD.  However,  at  the  time  of  our  study,  the  IBD-disability
ndex  had  not  yet  been  validated  in  patients  with  IBD.
Furthermore,  we  also  studied  variables  related  to  IBD
ith  potential  impact  on  disability.  Some  studies  have
eported  that  CD  carries  a  greater  risk  of  disability  than
lcerative  colitis.20,21 In  our  study,  there  was  no  statistically
igniﬁcant  difference  in  the  IBD-DS  scores  between  these
wo  groups  of  patients.  However,  in  CD,  unlike  UC,  mul-
iple  clinical  variables,  including  gender  and  the  presence
f  extra-intestinal  manifestations,  correlated  signiﬁcantly
ith  disability.  The  data  concerning  the  inﬂuence  of  gender
n  disability  are  still  contradictory.  Although,  some  stud-
es  show  no  differences,22 others  have  found  a  signiﬁcant
elationship  with  the  female  gender.6,8 Several  hypotheses
or  this  ﬁnding  are  frequently  reported  in  studies.  Psychoso-
ial  factors  and  coping  strategies  may  play  a  role  in  how
omen  deal  with  the  disease.23 Furthermore,  women  have
reater  disease-related  concerns  and  worries  about  being
reated  differently  as  a result  of  their  disease,24 and  are
lso  more  likely  to  report  concerns  related  to  attractive-
ess  and  body  Image.25,26 The  presence  of  extra-intestinal
anifestations7,20 was  also  previously  associated  with  a
reater  likelihood  of  temporary  or  permanent  work  disabil-
ty.  The  IBD  affects  not  only  the  ability  to  work,  but  other
mportant  domains  of  patients’  life.  In  this  context,  the  fact
hat  variables  previously  known  as  predictors  of  work  dis-
bility  remained  signiﬁcantly  related  to  disability  assessed
y  IBD-DS,  emphasizes  the  importance  of  the  latter  in  the
verall  assessment  of  disability  in  patients  with  IBD.
Unsurprisingly,  CD  and  UC  patients  with  a  sick  leave  or
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As  previously  reported,  most  disability  studies  have  tra-
ditionally  focused  on  work  and  employment.  A  recent
European  survey,14 presented  by  the  European  Federation
of  Crohn’s  &  Ulcerative  Colitis  Associations  (EFCCA)  in  part-
nership  with  the  European  Crohn’s  and  Colitis  Organization
(ECCO),  assessed  burden  of  IBD  in  Europe.  About  half  of  the
patients  responded  that  their  life  was  signiﬁcantly  affected
by  IBD  during  their  most  recent  ﬂare-up.  Of  these,  26%  had
more  than  25  days  of  annual  absence  due  to  IBD.  The  social
and  economic  impact  of  disability  in  IBD  patients  is  colos-
sal,  as  it  is  estimated  that  20%  of  patients  will  eventually
receive  a  disability  pension  and  over  10--25%  will  face  unem-
ployment.
In  this  topic,  the  comparison  between  studies  is  difﬁcult
due  to  the  different  socio-economic  factors  and  govern-
mental  regulations  that  determine  the  qualiﬁcations  for  a
sick  leave  or  a  disability  pension,  from  country  to  country.
Thus,  the  use  of  IBD-DS,  a  standard  measure  to  quantify
disability  in  IBD,  will  allow  a  more  uniform  and  objective
assessment  of  disability  in  IBD,  allowing  the  compari-
son  of  results  between  different  institutions  and  different
countries.
In  conclusion,  the  Portuguese  version  of  the  IBD-DS  is  a
valid  and  easily  applicable  instrument,  thereby  making  it  a
useful  tool  in  the  evaluation  of  disability  in  IBD.  The  appli-
cation  of  a  standard  measure  for  evaluating  disability  in  IBD
is  of  great  interest,  as  it  will  allow  for  a  better  perception  of
the  impact  of  disease  in  the  patient’s  life  and  an  objective




 sick  leave  or  a  disability  pension  as  well  as  adding  a  new
imension  to  the  assessment  of  response  to  therapy.
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nnex 1. Incapacidade na Doenc¸a Inﬂamatória
ntestinal  -- Questionário
ncapacidade na Doença Inflamatória Intestinal - Questionário
obilidade
. No mês passado teve alguma dificuldade em efetuar longas distâncias a pé
nflamatória intestinal?
enhuma [  ]; pouca [  ]; alguma [  ]; muita [  ]; sempre [  ]
. No  mês  passado teve  alguma  dificuldade  em  correr  longas  distâncias 
nflamatória intestinal?
enhuma [  ]; pouca [  ]; alguma [  ]; muita [  ]; sempre [  ]
. No  mês passado teve alguma  dificuldadeem  permanecer  sentado devido
nflamatória intestinal? 
enhuma [  ]; pouca [  ]; alguma [  ]; muita [  ]; sempre  [  ]
. No mês passado a sua doença afetou a sua capacidade de andar de carro, 
ão afetou [  ]; afetou pouco [  ]; afetou moderadamente [  ]; afetou muito [  ]; a
. No mês passado a sua doença afetou a sua capacidade de viajar, incluindo
vião ?
ão afetou [  ]; afetou pouco [  ]; afetou moderadamente [  ]; afetou muito [  ]; a
utocuidado
. No mês passado teve alguma dificuldade em tomar banho sozinho?
enhuma [  ]; pouca [  ]; alguma [  ]; muita [  ]; sempre [   ]
. Tem alguém que o/a ajude com a sua higiene pessoal?
IM [  ] NÃO [  ]
rincipais atividades devida diária
. No seu estado de saúde atual, qual o nível de dificuldade que sente ao rea 
ecessário no seu emprego ?
enhuma [  ]; pouca [  ]; alguma [  ]; muita [  ]; sempre  [  ]
2. No mês passado a sua doença inflamatória intestinal causou-lhe dificuldad
de exercer o seu tr abalh o ? 
nenhuma [  ]; pouca [  ]; alguma [  ]; muita [  ]; sempre  [  ]
3. No mês passado a sua doença inflamatória intestinal dificultou a realizaçã
regulares? (por exemplo: o trabalho em casa, passatempos, empreg o, festas 
não afetou [  ]; afetou pouco [  ]; afetou moderadamente [  ]; afetou muito [  ]; 
Problemas do foro gastroenterológico
1.No mês passado sentiu cólicas na barriga?
nenhumas [  ]; poucas [  ]; algumas [  ]; muitas [  ]; sempre [  ]
2. No mês passado teve que se levantar durante a noite para evacuar?
nunca [  ]; poucas vezes [  ];  algumas vezes [  ]; muitas vezes [  ]; sempre [ ]3. No mês passado esteve com diarreia?
nunca [  ]; poucas vezes [  ];  algumas vezes [  ]; muitas  vezes [  ]; sempre [  ]
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4. No mês passado esteve obstipado?
nunca [  ]; poucas vezes [  ];  algumas vezes [  ]; muitas vezes [  ]; sempre [ ]
5. No mês passado teve problemas por flatulência excessiva? 
nunca [  ]; poucas vezes [  ];  algumas vezes [  ]; muitas vezes [  ]; sempre [  ]
6. No mês passado teve dores de barriga ? 
nunca [  ]; poucas vezes [  ]; algumas vezes [  ]; muitas vezes [  ]; sempre [ ]
7. No mês passado teve dores no ânus durante a dejeção? 
nunca [  ]; poucas vezes [  ];  algumas vezes [  ]; muitas vezes [  ]; sempre [  ]
8. No mês passado teve dificuldadeem realizar adequadamente a  sua higien 
evacuado? 
nunca [  ]; poucas vezes [  ];  algumas vezes [  ]; muitas vezes [  ]; sempre [  ]
9. No mês passado teve incontinência para fezes sem se aperceber? 
nunca [  ]; poucas vezes [  ];  algumas vezes [  ]; muitas vezes [  ]; sempre [  ]
10. No mês passado o  número  de  vezes  que  foi  à casa  de  banho  para  
capacidade de viver normalmente? 
não afetou [  ]; afetou pouco [  ]; afetou moderadamente [  ];  afetou muito [  ];  a
11.No mês passado sentiu  algum inchaço na barriga?
nunca [  ]; poucas vezes [  ];  algumas vezes [  ]; muitas vezes [  ]; sempre [  ]
12. No mês passado teve vómi tos?
nunca [  ]; poucas vezes [  ]; algumas vezes [  ]; muitas vezes [  ]; sempre [ ]
13.No mês passado teve dificuldade em comer normalmente?
nunca [  ]; poucas vezes [  ];  algumas vezes [  ]; muitas vezes [  ]; sempre [  ]
14. No mês passado  teve dificuldade em ganhar peso?
nunca [  ]; poucas vezes [  ];  algumas vezes [  ]; muitas vezes [  ]; sempre [  ]
15.No mês passado s entiu náuseas ou enjoos ?
nunca [  ]; poucas vezes [  ];  algumas vezes [  ]; muitas vezes [  ]; sempre [  ]
16.No mês passado a sua doença inflam atória causou alguma: 
a. Dificuldade em ir às compras?
nenhuma [  ]; pouca [  ]; alguma [  ]; muita [  ]; sempre  [  ]
b. Dificuldade em trabalhar?
nenhuma [  ]; pouca [  ]; alguma [  ]; muita [  ]; sempre  [  ]
c.Dificuldade em so cializar com amigos ou família?
nenhuma [  ]; pouca [  ]; alguma [  ]; muita [  ]; sempre  [  ]
d. Dificuldade na sua relação íntima ou atividade sexual? 
nenhuma [  ]; pouca [  ]; alguma [  ]; muita [  ]; sempre  [  ]
e. Dificuldade na realização das suas atividades de tempos livres ? 
nenhuma [  ]; pouca [  ]; alguma [  ]; muita [  ]; sempre  [  ]17.No mês passado precisou de usar fralda por incontinência para fezes?
SIM [  ] NÃO [  ]
1 J.  Magalhães  et  al.
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stoma?
fetou sempre [ ]
exercício físico ou jogos?
fetou sempre [ ]
de de socializar com 
fetou sempre [  ] 
de para participar em
fetou sempre [  ] 2  
18.Tem uma Ileostomia ou colostomia ?
SIM [  ] NÃO [  ]
Se sim, no mês passado isso afetou  a sua vida? 
não afetou [   ]; afetou po uco [  ]; afetou moderadamente [  ]; afetou muito [  ]; a 
Se sim , no mês passado teve dificuldade em esvaziar o estoma ?
nenhuma [  ]; pouca [  ];  alguma [  ]; muita [  ]; sempre [   ]
Se sim , no mês passado preocupou-se com o que os outros pensam do seu e
nenhuma [  ]; pouca [  ]; alguma [  ]; muita [  ]; sempre [   ]
Se sim , no mês passado o seu estoma afetou a sua vida íntima?
não afetou [  ]; afetou pouco [  ]; afetou moderadamente [  ]; afetou muito [  ]; a
Se sim , no mês passado o seu estoma afetou a sua capacidade para realizar 
não afetou [   ]; afetou pouco [  ]; afetou moderadamente [  ]; afetou muito [  ]; a 
Estado Mental
1. No mês passado teve dificuldade em permanecer acordado durante o dia?
nenhuma [  ]; pouca [  ];  alguma [  ]; muita [   ]; sempre [   ]
2. No mês passado sentiu falta de energia?
nunca [  ]; poucas vezes  [  ];  algumas vezes [  ]; muitas vezes [  ]; sempre [  ]
3. No mês passado teve dificuldade em sentir-se motivado? 
nenhuma [  ]; pouca [  ];  alguma [  ]; muita [   ]; sempre [   ]
4. No mês passado teve dificuldade em dormir? 
nenhuma [  ]; pouca [  ];  alguma [  ]; muita [   ]; sempre [   ]
5. No mês passado teve dificuldade em concentrar-se?
nenhuma [  ]; pouca [  ];  alguma [  ]; muita [   ]; sempre [   ]
6. No mês passado teve dificuldade em lembrar-se das coisas?
nenhuma [  ]; pouca [  ];  alguma [  ]; muita [   ]; sempre [   ]
7. No mês passado sentiu-se deprimid o? 
nunca [  ]; po ucas vezes [  ];  algumas vezes [  ]; muitas vezes [  ]; sempre [  ] 
8. No mês passado sentiu-se ansios o? 
nunca [  ]; po ucas vezes [  ];  algumas vezes [  ]; muitas vezes [  ]; sempre [  ] 
Fatores Sociais 
1. No mês passado a  sua doença  inflamatória intestinal afetou a sua capacida
outras pessoas? 
não afetou [  ]; afetou pouco [  ]; afetou moderadamente [  ]; afetou muito [  ]; a
2. No mês passado a sua doença  inflam atória intestinal afetou a sua capacida
eventos na comunidade? 
não afetou [   ]; afetou po uco [  ]; afetou moderadamente [  ]; afetou muito [  ]; a3.No mês pass ado a sua doença inflamatória intestinal afetou o seu trabalho? 
não afetou [  ]; afetou po uco [  ]; afetou moderadamente [  ]; afetou muito [  ]; afetou sempre [  ] 
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4. No mês passado a sua doença inflamatória intestinal afetou a sua capacidad
trabalho (se aplicável)? 
não afetou [   ]; afetou pouco [  ]; afetou moderamente [  ]; afetou muito [  ]; afeto
5. No mês passado a sua doença inflamatória intestinal afetou a sua vida famili
não afetou [   ]; afetou pouco [  ]; afetou moderadamente [  ]; afetou muito [  ]; af
6. No mês passado a sua doença teve um impacto negativo na sua situação fin
não afetou [   ]; afetou po uco [  ]; afetou moderadamente [  ]; afetou muito [  ]; a
7. No mês passado teve qu e receber algum  apoio de um familiar próximo?
nunca [  ]; po ucas vezes [  ];  algumas vezes [  ]; muitas vezes [  ]; sempre [  ] 
8. No mês passado teve que receber apoio dos seus amigos? 
nunca [  ]; po ucas vezes [  ];  algumas vezes [  ]; muitas vezes [  ]; sempre [  ] 
9. No mês passado teve que receber apoio dos seus colegas de trabalho ou viz
nunca [  ]; po ucas vezes [  ];  algumas vezes [  ]; muitas vezes [  ]; sempre [  ] 
10.No mês passado teve que receber apoio do seu patrão no trabalho (se apl 
nunca [  ]; poucas vezes [  ]; algumas vezes [  ]; muitas vezes [  ]; sempre [ ]
11. No mês passado teve  que receber apoio de algum profissional de saúde (
médico de família) ?
nunca [  ]; poucas vezes  [  ]; al gumas vezes [  ]; muitas vezes [  ]; sempre [  ]
12.No mês passado teve que receber apoio de um nutricionista, enfermeira ou
nunca [  ]; poucas vezes  [  ]; al gumas vezes [  ]; muitas vezes [  ]; sempre [  ]
13. Tem alguém que o  ajude na sua higiene  diária, nas suas compras ou ou
diária?
NÃO [  ] SIM [  ] 
Se sim especifique .………………………………
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